Evidence map›Paper›PMID 41991742›Full record

ArticleNPJ precision oncology2026

AI-guided discovery of the IRF4-PAICS-LDHA axis as a multitarget hub linking tumor metabolism to CD8+ T cell exhaustion in DLBCL.

Zeyuan Wang, Liye Wang, Siyu Qian, Yue Zhang, Qing Yang, Zhenzhen Yang, Shaoxuan Wu, Meng Dong, Zhiqi Zhang, Xufeng Wei and 7 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zeyuan Wang *Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Liye Wang *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Siyu Qian *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yue ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Qing YangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhenzhen YangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Shaoxuan WuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Meng DongDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zhiqi ZhangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xufeng WeiDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Minglei YangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Hui MengDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Enjie LiuDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Guozhong JiangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xudong ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. feverxxd@126.com.
Wencai LiDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. liwencaipatho@126.com.
Qingjiang ChenDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. qingjiang_c@126.com.

Funding

Henan Provincial Key Scientific and Technological Research Project 262102310109Henan Provincial Natural Science Foundation General Project 252300421358Henan Provincial Science and Technology Research Project SBGJ202001008Noncommunicable Chronic Diseases-National Science and Technology Major Project 2025ZD0544300The Clinical Medical Scientist Training Program under the 'Three 100s' Initiative of Henan Province HNCMS202428
6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) features an immunosuppressive tumor microenvironment (TME), yet the molecular drivers connecting metabolic reprogramming to immune evasion remain poorly defined. Here, we deployed an integrative single-cell transcriptomic analysis combined with a machine learning (ML) framework to systematically identify key immune-suppressive hubs in DLBCL. Through ML-driven prioritization of a 33-gene panel, PAICS emerged as a central node within an immunosuppressive B-cell subgroup. Functional assays confirmed that PAICS promotes lymphoma proliferation, survival, and tumor growth while establishing an immunosuppressive TME-marked by reduced IFN‑γ, elevated TGF‑β and IL‑10, and enhanced CD8⁺ T cell exhaustion. Mechanistically, we uncovered the IRF4-PAICS-LDHA axis: IRF4 transcriptionally activates PAICS, which physically interacts with LDHA to augment its activity, thereby skewing the NAD⁺/NADH balance toward metabolic immunosuppression. Importantly, our AI-aided approach not only identified this axis but also predicted its vulnerability to metabolic intervention: both methotrexate treatment and LDHA knockdown restored metabolic balance, reversed T‑cell exhaustion, and suppressed tumor growth. These findings highlight the power of ML in uncovering multi-targetable metabolic-immune networks and in guiding therapeutic strategies to overcome immune evasion in DLBCL.

Identifiers

PMID41991742
PMCPMC13260363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.